Abstract
During the past five years, 21 patients with Stage III nodular malignant lymphoreticular tumors (MLT) have undergone total central lymphatic (TCL) irradiation. The irradiation must include the entire abdomen and Waldeyer's ring in addition to the usual regions encompassed by total nodal irradiation. A threshold dose of 2500-3000 rad in 20-45 days is received m each target volume. Every patient has been rendered free of all evidence of disease. One patient developed local recurrence and three had marginal recurrences; they are now free of disease 6-56 months after additional irradiation. Five patients have developed visceral dissemination and are receiving chemotherapy. All patients are alive (6-60 months, median 24 months). A prospective randomized trial has been established to compare TCL irradiation to the most favorable combination chemotherapy for patients with Stage III nodular MLT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 491-496 |
| Number of pages | 6 |
| Journal | International journal of radiation oncology, biology, physics |
| Volume | 1 |
| Issue number | 5-6 |
| DOIs | |
| State | Published - 1976 |
Keywords
- Malignant lymphoreticular tumors (MLT)
- Threshold dose
- Total central lymphatic irradiation (TCL)
- Total nodal irradiation
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Fingerprint
Dive into the research topics of 'Total central lymphatic irradiation for stage III nodular malignant lymphoreticular tumors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS